Oncology Central

Biomaterial-based local drug delivery to brain tumors

0

Glioblastoma (GBM) is the most prevalent and aggressive malignant brain tumor with a median survival from diagnosis of 12–15 months. Standard-of-care treatment consists of radical surgery followed by radiotherapy with concomitant systemic temozolomide. Nevertheless, due to the infiltrative nature of GBM, this treatment strategy almost universally fails to eradicate minimal volume residual disease, which typically recurs within 2 cm from the original lesion [1].

To view restricted content, please:
Share:

Leave A Comment

Please wait...

Would you like access to more immuno-oncology content?

Register with Oncology Central to find out the latest news, opinions and journal articles published in the oncology field by leading experts.